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Objectives: There are indications that institutional review board (IRB) members do not find it easy to assess
the risks and benefits in medical experiments, although this is their principal duty. This study examined how
IRB members assessed the risk/benefit ratio (RBR) of a specific phase II breast cancer clinical trial.
Participants and methods: The trial was evaluated by means of a questionnaire administered to 43
members of IRBs at six academic hospitals and specialised cancer centres in the Netherlands. The
questionnaire addressed: identification and estimation of inconvenience, toxicity, psychosocial distress,
and benefits of trial participation to patients; identification and estimation of benefits to future patients and
medical science; assessment of the trial’s RBR; and assessment of its ethical acceptability.
Results: Most IRB members expected trial participation to involve fairly or very serious inconvenience,
fairly severe to sometimes life-threatening toxicity, and serious psychological and social consequences.
Conversely, the perceived likelihood of benefits to patients was modest. Most regarded the study as
important, and the balance between risks and benefits to be favourable, and believed that the protocol
should be approved. The IRB members’ final judgement on the trial’s ethical acceptability was significantly
correlated with their RBR assessment of the protocol.
Conclusions: Because most patients who participate in clinical trials hope this will prolong their lives, it is
suggested that patient information should better describe the anticipated benefits—for example, the
likelihood of prolonging life. This would allow patients to make decisions regarding participation based on
realistic expectations.
T
here are indications that institutional review board (IRB)
members do not find it easy to assess the ratio of risks to
benefits in medical experiments, although this is one of
their principal duties.1–5 IRBs are legally required to evaluate
whether the risk/benefit ratio (RBR) is ‘‘reasonable’’,
‘‘proportional’’, or ‘‘favourable’’. Since there is no consensus
on the content of, and categories and criteria for, evaluating
the RBR, IRB evaluations, although usually based on long
term clinical experience, are unavoidably subjective and
intuitive. The lack of shared categories and criteria makes it
difficult to trace and discuss differences of opinion within an
IRB, and thereby reduces the chances that evaluation of the
ratio between risks and benefits will play a prominent role in
the final decision regarding the ethical acceptability of the
research. The difficulties with assessing the RBR sometimes
induce IRBs to leave the evaluation primarily to the potential
research participants, arguing that it is their right to
determine whether, from their perspective, the relation of
risks to benefits is reasonable. Whether this is ethically
acceptable, and whether very ill patients are capable of
making such stressful decisions, remains unclear.6–11
The most important contributions to the study of RBR
assessment of medical research involving humans have been
those of Levine and Meslin.1–3 12–17 Levine developed a set of
categories to distinguish between risks and benefits for
participating patients, for future patients, and for society at
large (scientific progress).14 These categories have been
further refined by distinguishing between different kinds or
dimensions of risks and benefits for participating patients—
for example, physical, psychological, social. Meslin devoted
special attention to risk assessment by IRB members.1 He
identified three ‘‘decision-making processes’’ in risk assess-
ment: identification, estimation, and evaluation of risks.
Using Levine’s and Meslin’s distinction between different
types of risks and benefits, between ‘‘risk’’ and ‘‘harm’’,
certain and uncertain risks, and between the phases of
identification, estimation, and evaluation of risks, we
designed a survey to study IRB members’ assessment of the
RBR for a specific phase II cancer clinical trial.
The current study represents the second stage of a four-
stage project examining the assessment of the RBR of phase
II and III cancer clinical trials by IRB members in the
Netherlands. The first stage consisted of semistructured
interviews with 53 IRB members regarding the RBR assess-
ment of phase II and III cancer clinical studies in general.18 19
This second stage of the research addresses two primary
questions: (1) what risks and benefits do IRB members
identify in a phase II breast cancer trial, and how do they
estimate and evaluate these risks and benefits? and (2) what
is their assessment of the RBR and the ethical acceptability of
the protocol?
PARTICIPANTS AND METHODS
Study participants, protocol evaluation, and
questionnaire
The study was conducted in the period 1998–1999. The IRBs
of eight Dutch academic hospitals and specialised cancer
centres were asked to participate. We did not select non-
academic hospitals because they do not evaluate sufficient
numbers of cancer clinical trials to be appropriate candidates
for such a study. Five of the eight IRBs agreed to participate.
All members of these IRBs (n = 64) were invited to take part
in the first stage of the study, of whom 52 agreed to do so.
Abbreviations: IRB, institutional review board; RBR, risk/benefit ratio
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One member of the IRB of a sixth Dutch teaching hospital
also agreed to participate. The primary reason for non-
participation was constraints on time. Of these 53 IRB
members, 10 declined to continue participation in this second
stage of the research, again, due largely to time constraints.
The final study sample on which the current analysis was
based included 43 members of six IRBs in six Dutch hospitals
(the Utrecht Academic Hospital, the Vrije Universiteit
Medical Center in Amsterdam, the Rotterdam Academic
Hospital, the Leiden Academic Hospital, the Netherlands
Cancer Institute/Antoni van Leeuwenhoek Hospital in
Amsterdam, and the Daniel den Hoed Hospital in
Rotterdam). The sample consisted of oncologists (21%),
other medical specialists (19%), family physicians (5%),
nurses (19%), and other disciplines (36%), including four
pharmacists, two ethicists, two behavioural scientists, one
statistician, and others. The respondents’ age ranged from 28
to 69 years. The majority were men (65%). Nine percent had
been IRB members for less than 1 year, 47% for 1–4 years,
23% for 4–7 years, and 21% for longer than 7 years.
An American phase II breast cancer clinical trial—which
had been approved in 1997—was selected for the study from
the website of the National Cancer Institute. (The trial was
used with permission of the authors and is entitled: A pilot
study of allogeneic peripheral blood stem cell transplantation
for patients with metastatic or recurrent breast cancer using a
conditioning regimen of busulfan and cyclophosphamide.)
We decided against a European or a Dutch protocol to avoid
the chance of distortions in the results due to the possible
familiarity of the research participants with the protocol. This
phase II trial was designed to investigate the efficacy and
toxicity of allogeneic stem cell transplantation in combina-
tion with high doses of chemotherapy for patients with
metastatic breast cancer. We selected a trial involving a very
intensive treatment because we believed this to be the most
effective approach to investigating the process of risk/benefit
assessment. This trial differs from the usual phase II studies
because it was expected to have high risks as well as
potentially large benefits, while most phase II trials are
expected to be less risky as well as less beneficial. The
rationale for using this ‘‘atypical’’ trial was as follows. We
expected that such a trial would result in more variation in
IRB members’ assessments of the RBR and of the ethical
acceptability of the protocol than a study with high risks but
small benefits or vice versa, or a study with low risks as well
as small benefits. The protocol evaluation was conducted by
means of a questionnaire consisting primarily of closed-
ended questions. We used closed questions because open
questions about the protocol evaluation will be asked in in-
depth interviews in the third phase of the research project.
The questionnaire had been previously pilot tested among
five IRB members or former IRB members, all of whom
participated in the main study. The respondents were asked
to study the protocol and the patient information, to
complete the questionnaire and to return it by mail. The
procedures took approximately 2 hours: 1 hour for studying
the protocol and 30–45 minutes to fill in the questionnaire.
The following topics were included in the questionnaire:
(1) identification and estimation of the inconvenience,
toxicity, psychosocial distress, and benefits of trial participa-
tion to patients; (2) identification and estimation of benefits
to future patients and medical science; (3) assessment of the
overall RBR of the study; and (4) assessment of the ethical
acceptability of the study. The questions asked were based on
the literature and can be found in the Appendix.1–3 12–17
Although this protocol does not provide any data about
psychological and social risks, we asked whether IRB
members believed these types of risk were present in the
study. The questions concerning the identification and
estimation of toxicity were based on a predetermined list of
toxicities drawn from the protocol itself. The specific aspects
of possible treatment toxicity that were assessed included:
likelihood, severity, duration, reversibility, and amenability to
treatment. The only aspects considered to be relevant for
assessing the psychosocial burden of the treatment were
likelihood, severity, and duration. The only aspects consid-
ered to be relevant for assessing the benefits of treatment
were likelihood, duration, and importance. The importance of
the benefits of the treatment was assessed directly, while that
of the risks was captured by the severity rating.
It could be argued that the details presented on the rating
of the toxicity and benefits would be more relevant if a
comparison were made with the actual ‘‘facts’’ as stated in
the protocol. However, in this study such a comparison was
not of primary interest or the focus of the research.
Statistical analysis
Descriptive statistics were generated with the SPSS software
program. The x2 statistic was used to test the relationship
between the IRB members’ assessment of the RBR of the
protocol and their assessment of the protocol’s ethical
acceptability.
RESULTS
Identification and estimation of risks and benefits
Inconvenience
As shown in table 1, hospital admission and time investment
(travel, waiting, etc.) were rated as the most inconvenient
aspects of trial participation.
Toxicity
Table 2 presents the evaluation of the most common
toxicities along five axes: likelihood, severity, duration,
reversibility, and amenability to treatment. There was broad
agreement among IRB members on the expected toxicity of
the treatment: hair loss, diarrhoea, nausea, vomiting, fatigue,
and organ toxicity were estimated by most IRB members as
very to fairly likely. Additional toxicities expected by IRB
members to be very or fairly likely were: mucositis, infection,
fertility problems/damage to offspring, bleeding, change of
skin colour, high blood pressure, tremors, painful hands and
feet, stomatitis, haematuria, genetic disturbances, and rejec-
tion of donor bone marrow.
Most respondents rated these toxic effects as fairly severe
to life threatening, expected hair loss and fatigue to last for
some months to years, and 30% and 44%, respectively,
expected organ toxicity and cognitive neurological problems
to last for some months to years. Although hair loss,
diarrhoea, and nausea and vomiting were expected to be
reversible, fatigue and organ toxicity were typically not. In
addition, half of the respondents expected cognitive/neuro-
logical problems to be irreversible or sometimes irreversible.
Although most expected some toxic effects to be amenable to
treatment, for hair loss and fatigue this was not the case.
Furthermore, half of the IRB members expected organ
toxicity and cognitive/neurological problems, and more than
one-third other toxicity, not to be treatable.
Psychosocial distress
Ninety-three percent of the IRB members believed trial
participation would entail psychological distress for patients
beyond that caused by the illness itself (data not presented in
tabular form). As shown in table 3, approximately 50%
expected patients to experience depression, 79% stress, and
88% uncertainty as a result of trial participation. Other forms
of psychosocial distress, such as loneliness, donor depen-
dence, and fear were identified by 16% of the IRB members.
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Seventy-two percent of the respondents believed trial
participation to be a social burden for patients (not presented
in tabular form). As reported in table 3, two-thirds expected a
strain on relationships with partners and on other social
contacts. Seven percent also mentioned long periods of illness
or a strain on patients’ professional life as expected stressors.
Benefits to participating patients
As indicated in table 4, 45% of respondents expected tumour
remission and 35% a longer symptom-free period to be fairly
or very likely. Only a minority of IRB members expected that
other benefits would accrue to patients (except for hope).
Benefits to future patients and science
Sixty-eight percent of the IRB members were unable to
estimate how many patients in the Netherlands would
benefit annually from the experimental treatment, should it
prove effective. Most rated the clinical trial as fairly to very
important (8% of very great importance, 39% of great
importance, 39% of moderate importance).
Final assessment of the risk/benefit ratio and the
ethical acceptabili ty of the research
Thirty percent of the IRB members believed that the risks of
the protocol outweighed the benefits, 21% believed that the
benefits outweighed the risks, and 35% assigned approxi-
mately equivalent weights to the risks and benefits. Thirty-
seven percent said they would approve the protocol and 44%
would recommend approval after revision. Although 44% of
the IRB members believed that the risks outweighed the
benefits or were unable to evaluate the RBR, only 18% said
they would reject the protocol or could not judge its ethical
acceptability. There was a significant relationship between
their assessment of the RBR and the ethical acceptability of
the trial (p , 0.031). Most of the IRB members (83%) who
believed that the risks of the protocol outweighed the
benefits said they would reject the protocol; 17% of them
would approve the protocol or would approve it after revision.
More than half (54%) of those who believed the benefits
outweighed the risks, or who assigned approximately
equivalent weights to the risks and benefits, said they would
approve it; less than half would reject it or would approve it
after revision.
DISCUSSION
The aims of the current study were to examine how
individual IRB members assess the diverse risks and benefits
of a specific phase II cancer protocol, and to examine how
they come to their final assessment of the RBR and the
ethical acceptability of the proposed trial. First, we were
interested in determining what type of risks and benefits IRB
members identify in evaluating a particular phase II cancer
protocol, and how they estimate and evaluate these risks and
benefits. The results indicate that most IRB members felt
competent to estimate specific aspects of the risks and
benefits such as likelihood and severity (although the
expected duration of such risks and benefits proved more
difficult to evaluate), to determine the RBR, and to assess the
ethical acceptability of the trial. These findings are consistent
with those reported previously for IRB members’ estimations
for phase II cancer protocols in general.18 19
The results also indicate that, besides inconvenience and
fairly severe to sometimes life-threatening physical risks
(toxicity), these IRB members identified several serious
psychological and social risks of trial participation. This is
in line with the distinction made by Levine between different
types of risks for patients participating in medical experi-
ments (physical, psychological, social).14 The results further
indicate that, while IRB members believed the research to be
important, they expected only modest benefits to accrue to
the participating patients. Although a substantial percentage
rated benefits to patients such as tumour remission (45%), a
longer symptom-free period (35%), and hope (65%) to be
fairly or very likely, only a few expected this to be the case
with respect to prolongation of life, reduction in pain, less
toxicity than an alternative treatment (for example, no
treatment), and a better quality of life.
Secondly, we investigated the IRB members’ assessment of
the RBR and the ethical acceptability of the protocol. Most
believed that the benefits outweighed the risks, or that risks
and benefits had nearly equal weight, and most wanted the
trial to take place. Furthermore, as one would expect, a
significant association was observed between assessment of
the RBR and assessment of the ethical acceptability of the
trial. This means that the IRB members’ evaluation of the
RBR played a significant role in their final decision regarding
the ethical acceptability of the trial.
Most cancer patients participate in trials because they hope
for a treatment effect in terms of prolongation of life.6 20 21
Because we did not study the letter of informed consent, we
cannot say what patients were told about their potential
benefit in the trial. However, considering that patients
themselves have to carry the risks and the weight they
assign to prolongation of their life, it can be doubted whether
patients having the same information as the IRB members
would come to a RBR assessment similar to that of the IRB
members. This observation underlines the need to be open
and honest when informing patients, and it provides a very
strong argument for taking the perspectives of patients into
account when determining the RBR of trials.
A number of the study’s limitations should be mentioned.
First, we evaluated only one specific phase II cancer protocol.
Although it would have been preferable to ask the IRB
members to evaluate a range of protocols, this was not
feasible given the rather labour intensive nature of the
research. We believe that the trial protocol we selected for
review was reasonably representative of phase II cancer
clinical trials in general, although, as we stated earlier, the
treatment schedule was quite intensive.
Table 1 Estimation by IRB members of the inconvenience of the phase II study for
participating patients (n = 43) (%).
Very Fairly Not very Not at all Not applicable*
Hospital admission 35 58 7 0 0
IV treatment 5 28 65 2 0
Additional examinations 17 56 27 0 0
Extra control visits 7 49 39 0 5
Time investment (travel, waiting,
etc.)
23 49 23 5 0
*Respondents could choose this alternative when they believed a certain form of inconvenience was not present in
the trial.
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Secondly, the participants were all drawn from the IRBs of
Dutch academic hospitals or specialised cancer centres.
Whether our results can be generalised to other types of
hospitals or to other countries is uncertain. The settings in
which European and American IRBs operate may differ in
certain respects. For example, in the USA there is generally a
greater concern with protecting hospitals and physicians
from possible legal action than is the case in Europe.
However, the structure, objectives, and procedures of IRBs
are similar, regardless of whether they are American or
European. Thus we are fairly confident that our results can
reasonably be extended to IRBs in general.
Finally, we would note that our study was based on
questionnaire rather than observational data, and that we
queried individual members rather than investigating the
IRBs as a whole. We realise that the decisions taken by IRBs
are often collective ones, and emerge from discussions and
debates that take place during IRB meetings. Nevertheless,
each IRB member brings his or her own perspective to such
deliberations, and is expected to be well prepared to
participate actively in the decision-making process. At the
same time, we would recognise the value of other types of
research—for example, observational studies, that would
better be able to capture the group dynamics involved in IRB
decision making. In a future article we will report the results
of the latter stage of the current study in which such
observational techniques were employed.
SUMMARY
First, most IRB members estimated hope to be as important
as physical benefits to patients (about 65% believed physical
benefits to be fairly or very important, see table 4), but more
likely (65% believed hope to be fairly or very likely versus 7–
45% for the physical benefits, see table 4). Hope is, of course,
important. Although we did not study why patients want to
participate in clinical trials, the literature shows that most do
so hoping that this will prolong their lives.21 This hope is in
danger of becoming irrational when the chances for survival
are very low. We observe that the IRB members considered
survival benefit to be unlikely compared with tumour
remission and a longer symptom-free period, but they
regarded the psychological benefit of hope to be as important
as physical benefits in their RBR assessment. If hope is an
almost illusionary benefit, is it ethically acceptable to include
it in assessing the RBR? We know from earlier studies that
patients’ and medical doctors’ expectations of benefit from
participation in medical experiments are different.20 It would
be an improvement if patient information sheets paid more
attention, as they normally do to the risks, to the possible
benefits to participants. This would prevent patients’ hope
from becoming irrational.
Secondly, although the IRB members evaluated the risks to
be fairly severe to sometimes life-threatening, most believed
that the benefits outweighed the risks, or that risks and
benefits had a nearly equal weight, and most wanted the trial
to take place. Their final judgement on the protocol’s ethical
acceptability was significantly correlated with their RBR
assessment of the protocol. Thus, evaluation of the risks and
benefits actually formed part of the IRB members’ final
evaluation of the protocol’s ethical acceptability.
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APPENDIX: PARAMETERS STUDIED IN THE SURVEY
OF A PHASE II CANCER PROTOCOL
IDENTIFICATION AND ESTIMATION OF
INCONVENIENCE FOR THE RESEARCH
PARTICIPANTS
‘‘How burdensome do you think this situation is for the
patient?’’
Admission of the patient to the hospital, IVs, extra
examinations, extra control visits, and time investment
(travel, waiting, etc.).
(Answers were scored on a 4-point Likert scale from ‘‘very
burdensome’’ to ‘‘not burdensome at all’’.)
IDENTIFICATION AND ESTIMATION OF TOXICITY
FOR THE RESEARCH PARTICIPANTS
‘‘What kind of toxicity do you believe would happen during
and/or after the research?’’
They could choose between hair loss, diarrhoea, nausea,
vomiting, fatigue, organ toxicity, cognitive neurological
problems, or other toxicity.
(If a certain kind of toxicity was believed not to happen,
this answer was scored as an answer to the next question
concerning the likelihood of the toxicity as that the likelihood
would be ‘‘not high at all’’. If the toxicity was believed to
happen, the respondent was asked how he or she estimated
the likelihood of this toxicity and his or her answer was also
scored as an answer to the next question concerning the
likelihood of the toxicity.)
‘‘Indicate the likelihood, severity, duration, reversibility
and amenability to treatment for the patient during and/or
after experimental treatment of the following: hair loss,
diarrhoea, nausea, vomiting, fatigue, organ toxicity, cognitive
neurological problems, or other toxicity.’’
(Answers were scored on a 4-point Likert scale from: (1)
‘‘very high’’ to ‘‘not high at all’’; (2) ‘‘mild’’ to ‘‘life
threatening’’; (3) ‘‘a few days’’ to ‘‘years’’; (4) ‘‘reversible’’
to ‘‘irreversible’’; and (5) ‘‘amenable to treatment’’ to ‘‘not
amenable to treatment’’.)
IDENTIFICATION AND ESTIMATION OF
PSYCHOSOCIAL DISTRESS FOR THE RESEARCH
PARTICIPANTS
‘‘Do you believe participation in the experimental treatment
will impose an extra psychological burden (beyond the
burden imposed by the illness and previous treatment) for
the patient?’’
(Answers were scored as: (1) ‘‘yes’’; (2) ‘‘no’’; (3) ‘‘don’t
know’’.)
‘‘Do you believe participation in the experimental treat-
ment will place an extra social burden (beyond the social
burden imposed by the illness and previous treatment alone)
on the patient?’’
(Answers were scored as: (1) ‘‘yes’’; (2) ‘‘no’’; (3) ‘‘don’t
know’’.)
‘‘Indicate the likelihood, severity, and duration of the
following psychosocial stress for the patient during and/or
after the experimental treatment as an extra psychological
and social burden (over and above the stress related to the
illness and treatment): depression, stress, uncertainty, extra
strain on relationships with partners, extra strain on other
social contacts, and loss of prestige.’’
(Answers were scored on a 4-point Likert scale: (1) ‘‘very
high’’ to ‘‘not high at all’’; (2) ‘‘not so severe’’ to ‘‘very
severe’’; (3) ‘‘a few days’’ to ‘‘years’’.)
IDENTIFICATION AND ESTIMATION OF BENEFITS TO
THE RESEARCH PARTICIPANTS
‘‘What kind of benefits do you think participating patients
will obtain during and/or after the research?’’
They could choose between tumour remission, prolonga-
tion of life, longer symptom-free periods, less pain, better
quality of life, hope, or other benefits.
(If a certain kind of benefit was believed not to happen,
this answer was scored as an answer to the next question
concerning the likelihood of the benefit as that the likelihood
would be ‘‘not high at all’’. If the benefit was believed to
happen, the respondent was asked how he or she estimated
the likelihood of this benefit and his or her answer was also
scored as an answer to the next question concerning the
likelihood of the benefit.)
‘‘Indicate the likelihood, duration, and importance of the
following benefits for the patient during and/or after
experimental treatment: tumour remission, prolongation of
life, longer symptom-free periods, less toxicity than alter-
native treatment, less pain, better quality of life, hope, or
other benefits.’’
(Answers were scored on a 4-point Likert scale: (1) ‘‘very
high’’ to ‘‘not high at all’’; (2) ‘‘a few days’’ to ‘‘years’’; (3)
‘‘very important’’ to ‘‘not important at all’’.)
IDENTIFICATION AND ESTIMATION OF BENEFITS TO
FUTURE PATIENTS AND MEDICAL SCIENCE
‘‘Indicate how many patients would benefit every year in the
Netherlands from the experimental treatment should it prove
effective.’’
‘‘Indicate the importance of the research study.’’
(The first was an open question; answers to the second
question were scored on a 4-point Likert scale from ‘‘very
important’’ to ‘‘not important at all’’.)
RISK/BENEFIT RATIO ASSESSMENT OF THE STUDY
‘‘What is your final assessment of the risk/benefit ratio of the
study?’’
(Possible answers included: (1) ‘‘the risks outweigh the
benefits’’; (2) ‘‘the benefits outweigh the risks’’; (3) ‘‘the
risks and benefits weigh approximately the same’’; or (4)
‘‘don’t know’’.)
ASSESSMENT OF THE ETHICAL ACCEPTABILITY OF
THE STUDY
‘‘What is your final assessment of the study?’’
(Possible answers included: (1) ‘‘approve’’, (2) ‘‘needs
revision’’; (3)’’reject’’; (4) ‘‘don’t know’’.)
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